{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:56:30Z","timestamp":1758815790932,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["843004102"],"award-info":[{"award-number":["843004102"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Approximately 40% of the newly diagnosed patients with advanced ovarian cancer are aged 70\u2009years or older. Standard treatment for advanced disease consists of cytoreductive surgery and combination chemotherapy. In older patients, standard treatment is often withheld or prematurely stopped due to suspected frailty. It remains challenging to distinguish fit elderly patients who can endure standard therapy from frail patients who may benefit from an adapted treatment strategy. As a comprehensive geriatric assessment (CGA) can contribute to the identification of frail patients and improve tailored therapy in this population, screening tests were developed to select those who may benefit from a CGA. However, the use of these geriatric screening tests has rarely been compared with usual clinical care. The GERSOC-trial will evaluate whether geriatric screening in elderly patients with advanced-stage ovarian cancer improves treatment completion and quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This pragmatic, cluster randomised controlled trial will be conducted at a minimum of 20 hospitals in the Netherlands. Hospitals are randomly assigned to geriatric screening care (in which a geriatric screening comprised of the G8 questionnaire and the Timed Up and Go test is performed), or care as usual (in which current usual care is continued). A total of 320 patients aged \u2265\u200970\u2009years with primary, advanced-stage ovarian carcinoma will be included. Patients considered fit on geriatric screening will receive standard treatment; patients who are considered unfit will be referred to a geriatrician for analysis and treatment advice. The primary outcome is the percentage difference in completed standard and adapted therapies between the two study arms. Secondary outcomes include quality of life, cost-effectiveness and survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This trial aims to gather evidence for the use of geriatric screening in treatment decision-making in elderly patients with advanced ovarian cancer. If proven feasible, beneficial and cost-effective, geriatric screening may be implemented in routine clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>Netherlands Trial Registry, ID:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.trialregister.nl\/trial\/6745\">NL6745<\/jats:ext-link>. Registered on 2 August 2017.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13063-020-4157-y","type":"journal-article","created":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T14:02:39Z","timestamp":1582380159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["GERiatric Screening in the treatment of elderly patients with Ovarian Carcinoma (GERSOC): study protocol for a pragmatic, cluster randomised controlled trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4346-6324","authenticated-orcid":false,"given":"Neeltje J.","family":"van Soolingen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina H.","family":"Smorenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marije E.","family":"Hamaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim G.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valesca P.","family":"Ret\u00e8l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christianne A. R.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lonneke V.","family":"van de Poll-Franse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes W.","family":"Trum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,22]]},"reference":[{"key":"4157_CR1","volume-title":"Global Cancer Observatory: Cancer Today","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2018. https:\/\/gco.iarc.fr\/today. Accessed 31 Jan 2020."},{"unstructured":"The Netherlands Cancer Registry (NCR), IKNL. 2019. https:\/\/iknl.nl\/nkr-cijfers. Accessed 31 Jan 2020.","key":"4157_CR2"},{"issue":"2","key":"4157_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ygyno.2018.02.017","volume":"149","author":"MS Schuurman","year":"2018","unstructured":"Schuurman MS, Kruitwagen RFPM, Portielje JEA, Roes EM, Lemmens VEPP, van der Aa MA. Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis. Gynecol Oncol. 2018;149(2):270\u20134.","journal-title":"Gynecol Oncol"},{"unstructured":"Guideline Commission Gynaecologic Oncology (CRGO). Dutch Guideline Epithelial Ovarian Carcinoma, version 2.2. 2018. https:\/\/www.oncoline.nl\/ovariumcarcinoom. Accessed 31 Jan 2020.","key":"4157_CR4"},{"issue":"28","key":"4157_CR5","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","volume":"34","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(28):3460\u201373.","journal-title":"J Clin Oncol"},{"issue":"29","key":"4157_CR6","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1200\/JCO.2013.49.6125","volume":"31","author":"H Wildiers","year":"2013","unstructured":"Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, et al. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. J Clin Oncol. 2013;31(29):3711\u20138.","journal-title":"J Clin Oncol"},{"key":"4157_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1186\/s12885-015-1947-9","volume":"15","author":"E Fourcadier","year":"2015","unstructured":"Fourcadier E, Tr\u00e9tarre B, Gras-Aygon C, Ecarnot F, Daur\u00e8s JP, Bessaoud F. Under-treatment of elderly patients with ovarian cancer: a population based study. BMC Cancer. 2015;15:937.","journal-title":"BMC Cancer"},{"issue":"29","key":"4157_CR8","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2010.34.1552","volume":"29","author":"KM Fairfield","year":"2011","unstructured":"Fairfield KM, Murray K, Lucas FL, Wierman HR, Earle CC, Trimble EL, et al. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. J Clin Oncol. 2011;29(29):3921\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4157_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ygyno.2004.12.026","volume":"97","author":"HAAM Maas","year":"2005","unstructured":"Maas HAAM, Kruitwagen RFPM, Lemmens VEPP, Goey SH, Janssen-Heijnen ML. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol. 2005;97(1):104\u20139.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"4157_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/IGC.0000000000000418","volume":"25","author":"R Sabatier","year":"2015","unstructured":"Sabatier R, Calderon B Jr, Lambaudie E, Chereau E, Provansal M, Cappiello MA, et al. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. Int J Gynecol Cancer. 2015;25(5):815\u201322.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"4157_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/ijgc-2018-000026","volume":"29","author":"IC van Walree","year":"2019","unstructured":"van Walree IC, van Soolingen NJ, Hamaker ME, Smorenburg CH, Louwers JA, van Huis-Tanja LH. Treatment decision-making in elderly women with ovarian cancer: an age-based comparison. Int J Gynecol Cancer. 2019;29(1):158\u201365.","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"4157_CR12","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2015.63.4592","volume":"34","author":"HJ Tan","year":"2016","unstructured":"Tan HJ, Saliba D, Kwan L, Moore AA, Litwin MS. Burden of geriatric events among older adults undergoing major cancer surgery. J Clin Oncol. 2016;34(11):1231\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4157_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ygyno.2008.03.008","volume":"110","author":"KN Moore","year":"2008","unstructured":"Moore KN, Reid MS, Fong DN, Myers TKN, Landrum LM, Moxley KM, et al. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008;110(2):133\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4157_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/IGC.0b013e3181c10c04","volume":"20","author":"C Fotopoulou","year":"2010","unstructured":"Fotopoulou C, Savvatis K, Steinhagen-Thiessen E, Bahra M, Lichtenegger W, Sehouli J. Primary radical surgery in elderly patients with epithelial ovarian cancer: analysis of surgical outcome and long-term survival. Int J Gynecol Cancer. 2010;20(1):34\u201340.","journal-title":"Int J Gynecol Cancer"},{"doi-asserted-by":"publisher","unstructured":"Kievit SB, Smorenburg CH, Hamaker ME, Trum JW. Treatment patterns in elderly women with ovarian cancer: single center experience in the Netherlands. Eur J Gynaecol Oncol. 2017. https:\/\/doi.org\/10.12892\/ejgo3985.2017.","key":"4157_CR15","DOI":"10.12892\/ejgo3985.2017"},{"issue":"9868","key":"4157_CR16","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381","author":"A Clegg","year":"2013","unstructured":"Clegg A, Young J, Iliffe S, Olde Rikkert M, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752\u201362.","journal-title":"Lancet."},{"issue":"24","key":"4157_CR17","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595\u2013603.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4157_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/annonc\/mdu210","volume":"26","author":"L Decoster","year":"2015","unstructured":"Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol. 2015;26(2):288\u2013300.","journal-title":"Ann Oncol"},{"issue":"8","key":"4157_CR19","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"CA Bellera","year":"2012","unstructured":"Bellera CA, Rainfray M, Mathoulin-P\u00e9lissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166\u201372.","journal-title":"Ann Oncol"},{"issue":"10","key":"4157_CR20","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1016\/S1470-2045(12)70259-0","volume":"13","author":"ME Hamaker","year":"2012","unstructured":"Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012;13(10):e437\u2013e44.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4157_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo D, Richardson S. The timed \"up & go\": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"4157_CR22","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1080\/0284186X.2016.1219047","volume":"55","author":"NM Verweij","year":"2016","unstructured":"Verweij NM, Schiphorst AH, Pronk A, van den Bos F, Hamaker ME. Physical performance measures for predicting outcome in cancer patients: a systematic review. Acta Oncol. 2016;55(12):1386\u201391.","journal-title":"Acta Oncol"},{"unstructured":"Nederlandse Vereniging voor Klinische Geriatrie. Dutch Guideline Comprehensive Geriatric Asssessment. 2010. https:\/\/richtlijnendatabase.nl\/richtlijn\/comprehensive_geriatric_assessment_cga\/cga_-_korte_beschrijving.html. Accessed 31 Jan 2020.","key":"4157_CR23"},{"issue":"5","key":"4157_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"4157_CR25","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","volume":"39","author":"E Greimel","year":"2003","unstructured":"Greimel E, Bottomley A, Cull A, Waldenstrom AC, Arraras J, Chauvenet L, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39(10):1402\u20138.","journal-title":"Eur J Cancer"},{"issue":"11","key":"4157_CR26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"key":"4157_CR27","volume-title":"Handleiding iMTA Medical Consumption Questionnaire (iMCQ)","author":"C Bouwmans","year":"2013","unstructured":"Bouwmans C, Hakkaart-van Roijen L, Koopmanschap M, Krol M, Severens H, Brouwer W. Handleiding iMTA Medical Consumption Questionnaire (iMCQ). Rotterdam: institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam; 2013."},{"issue":"7441","key":"4157_CR28","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/bmj.328.7441.702","volume":"328","author":"MK Campbell","year":"2004","unstructured":"Campbell MK, Elbourne DR, Altman DG, CONSORT group. CONSORT statement: extension to cluster randomised trials. BMJ. 2004;328(7441):702\u20138.","journal-title":"BMJ."},{"issue":"2","key":"4157_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/insr.12214","volume":"85","author":"PC Austin","year":"2017","unstructured":"Austin PC. A tutorial on multilevel survival analysis: Methods, models and applications. Int Stat Rev. 2017;85(2):185\u2013203.","journal-title":"Int Stat Rev"},{"key":"4157_CR30","doi-asserted-by":"publisher","DOI":"10.4324\/9780203852279","volume-title":"Multilevel analysis: Techniques and applications","author":"JJ Hox","year":"2010","unstructured":"Hox JJ. Multilevel analysis: Techniques and applications. 2nd ed. New York: Routledge; 2010.","edition":"2"},{"key":"4157_CR31","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511610806","volume-title":"Applied multilevel analysis. A practical guide. 1th ed","author":"JWR Twisk","year":"2006","unstructured":"Twisk JWR. Applied multilevel analysis. A practical guide. 1th ed. Cambridge: Cambridge University Press; 2006."},{"key":"4157_CR32","volume-title":"Applied longitudinal data analysis for epidemiology. A Practical Guide. 1th ed","author":"JWR Twisk","year":"2003","unstructured":"Twisk JWR. Applied longitudinal data analysis for epidemiology. A Practical Guide. 1th ed. Cambridge: Cambridge University Press; 2003."},{"issue":"11","key":"4157_CR33","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","volume":"48","author":"K Cocks","year":"2012","unstructured":"Cocks K, King MT, Velikova G, de Castro G Jr, Martyn St-James M, Fayers PM, et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012;48(11):1713\u201321.","journal-title":"Eur J Cancer"},{"issue":"11","key":"4157_CR34","doi-asserted-by":"publisher","first-page":"e0187477","DOI":"10.1371\/journal.pone.0187477","volume":"12","author":"Tim A. Kanters","year":"2017","unstructured":"Kanters TA, Bouwmans CAM, van der Linden N, Tan SS, Hakkaart-van Roijen L. Update of the Dutch manual for costing studies in health care. PLoS One. 2017;12(11):e0187477.","journal-title":"PLOS ONE"},{"key":"4157_CR35","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. 1th ed. Oxford: Oxford University Press; 2006.","edition":"1"},{"key":"4157_CR36","volume-title":"Cost-effectiveness in practice","author":"J Zwaap","year":"2015","unstructured":"Zwaap J, Knies S, van der Meijden C, Staal P, van der Heiden L. Cost-effectiveness in practice. Diemen: Zorginstituut Nederland; 2015. https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2015\/06\/16\/cost-effectiveness-in-practice. Accessed 31 Jan 2020"},{"issue":"5","key":"4157_CR37","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"JA Mauskopf","year":"2007","unstructured":"Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health. 2007;10(5):336\u201347.","journal-title":"Value Health"},{"unstructured":"European Medicines Agency - Committee for Medicinal Products for Human Use. Guideline on Data Monitoring Committees. London: European Medicines Agency; 2005. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-data-monitoring-committees_en.pdf. Accessed 31 Jan 2020.","key":"4157_CR38"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4157-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-4157-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4157-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T23:46:13Z","timestamp":1722469573000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-4157-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,22]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4157"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-4157-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2020,2,22]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study will be conducted according to the principles of the Declaration of Helsinki (version 7, October 2013) and the Guidelines for Good Clinical Practice and in accordance with the WMO and the Dutch law in general. Ethical approval has been obtained from the accredited MREC of The Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek (MREC AVL, reference number M17GSC \/ NL62356.031.17) for the original protocol (December 14, 2017) and all amendments. In all participating sites additional local approval was obtained. Written informed consent will be obtained from every participant before inclusion in the trial. Patients will be informed about and subsequently included in the trial by the treating physician or nurse. Patients are asked for permission to be approached for participation in follow-up studies on the informed consent form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}